<DOC>
	<DOCNO>NCT00406744</DOCNO>
	<brief_summary>Choroidal neovascularization lead cause visual loss people older 60 year treatment perform multicentric study Lucentis ( Ranibizumab ) significant improval visual acuity . In institution evaluate efficacy bevacizumab several pathology dont know would result use dose several time . Our purpose determine efficacy bevacizumab improve stabilize visual acuity two intravitreal inyections bevacizumab .</brief_summary>
	<brief_title>Efficacy Retreatments With Intravitreal Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>* Any visual acuity OCT : Central foveal thickness great 300 u evidence subretinal fluid . Active angiogram leakage * Basal Inflammatory disease Endoftalmitis history Lesions big 5400 u scar great 50 % lesion .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>neovascularization</keyword>
</DOC>